EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A preliminary cost-utility analysis of routine myasthenia gravis and thyroid dysfunction screening in acquired comitant Esotropia

Worapot Srimanan iD, Phawasutthi Keokajee, Sunita Sawangsribanterng

PLOS One · 28.05.2026 · 21 (5) · e0350280

DOI: 10.1371/journal.pone.0350280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 28.05.2026. Verfasst von Worapot Srimanan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Ophthalmology, Phramongkutklao Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Myasthenia Gravis, Thyroid Function Tests, Thyroid Diseases. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the cost-effectiveness of routine screening for acetylcholine receptor antibody (AChR-Ab) and thyroid function tests (TFT) in patients with acquired comitant esotropia (ACE) without overt signs of myasthenia gravis (MG) or thyroid eye disease (TED). A retrospective cost–utility analysis was conducted in 110 patients at a Thai tertiary hospital between 2014 and 2024. A decision tree combined with a 10-year Markov model compared two strategies: no routine screening (symptom-triggered testing) and universal baseline screening with AChR-Ab and TFT. Costs were expressed in 2024 Thai Baht (THB) from a healthcare sector perspective, and outcomes were measured in quality-adjusted life years (QALYs). Model uncertainty was assessed using one-way sensitivity analyses and probabilistic sensitivity analysis with 10,000 simulations, incorporating downstream costs of follow-up, confirmatory evaluation, and treatment. In the base-case analysis incorporating real-world diagnostic accuracy, universal screening yielded higher QALYs (109.56 vs. 105.45) but also higher costs (฿2,826,680 vs. ฿1,653,500), resulting in an incremental cost-effectiveness ratio (ICER) of ฿285,360 per QALY gained. This exceeded Thailand’s willingness-to-pay threshold of ฿160,000–200,000 per QALY, indicating that universal screening was not cost-effective. Probabilistic sensitivity analysis showed that most simulations were located in the northeast quadrant of the cost-effectiveness plane, reflecting greater effectiveness with higher cost, with many exceeding the willingness-to-pay threshold. Key drivers included MG prevalence, utility loss from undiagnosed MG, and AChR-Ab test cost. TFT screening contributed minimal benefit due to the very low prevalence of thyroid dysfunction. Universal AChR-Ab screening may improve early detection of MG in ACE, but it was not cost-effective under current assumptions. Exploratory targeted screening appeared relatively more efficient, and symptom-triggered thyroid testing may be a more appropriate approach. These findings are preliminary and require validation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisMyasthenia GravisThyroid Function TestsThyroid DiseasesHumansCost-Effectiveness AnalysisFemaleRetrospective StudiesMaleQuality-Adjusted Life YearsMiddle AgedAdultReceptors, CholinergicThailandMass Screening

Substanzen

Receptors, Cholinergic

Autor:innen und Institutionen

  • Division of Ophthalmology, Phramongkutklao Hospital, Bangkok, Thailand.

ORCID-Profile: Worapot Srimanan

Zitieren

APA

Srimanan, W., Keokajee, P., & Sawangsribanterng, S. (2026). A preliminary cost-utility analysis of routine myasthenia gravis and thyroid dysfunction screening in acquired comitant Esotropia. PLOS One, 21(5), e0350280. https://doi.org/10.1371/journal.pone.0350280

Vancouver

Srimanan W, Keokajee P, Sawangsribanterng S. A preliminary cost-utility analysis of routine myasthenia gravis and thyroid dysfunction screening in acquired comitant Esotropia. PLOS One. 2026;21(5):e0350280. doi:10.1371/journal.pone.0350280

BibTeX
@article{Srimanan2026,
  author = {Srimanan, Worapot and Keokajee, Phawasutthi and Sawangsribanterng, Sunita},
  title = {A preliminary cost-utility analysis of routine myasthenia gravis and thyroid dysfunction screening in acquired comitant Esotropia},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {e0350280},
  doi = {10.1371/journal.pone.0350280}
}
Kostenlos starten →